Company ProfilePremium

Enzyme Development Corporation

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Enzyme Development Corporation - Company showcase

Year Founded & Workforce

1953

18 Employees

Enzyme Development Corporation logo

Enzyme Development Corporation Employee Contacts

3 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Enzyme Development Corporation Overview

Enzyme Development Corporation is a niche, family-owned U.S. specialty enzyme company founded in 1953. It is headquartered in Manhattan, and its manufacturing, quality-control, regulatory and warehousing operations are in Scranton, Pennsylvania. Its main distinction is that it describes itself as the only papain producer in the Western Hemisphere. It also claims the same position for ficin and thistle rennet, giving it an unusual franchise in botanical (plant-derived) proteases at a time when food manufacturers increasingly want clean-label, non-GMO, vegan, kosher, halal and organic-compliant processing aids. Around this botanical core, EDC sells a broad catalogue of microbial carbohydrases, proteases, peptidases and lactases. These come from solid-state and submerged fermentation organisms (Aspergillus, Bacillus, Trichoderma, Rhizopus, Kluyveromyces) and are sold under the Enzeco®, Panol®, Liquipanol®, Enzobake®, Enzopharm®, Multizyme®, Adjuzyme®, Fresh-N® and Thistlezyme® brands. EDC competes on application expertise, custom blending, responsive service and certification breadth rather than scale. It serves flavour houses, pet food, meat, dairy, baking, brewing and distilling, starch processing, supplements and animal feed customers across the Americas, Europe and Asia.


The company's own description

EDC describes itself as a biotechnology company specialising in enzymes for food processing, animal feed, nutritional supplements, brewing and distilling. Its corporate office is in New York City and its factory is in Scranton (LinkedIn company page). The About page lists its value proposition as more than 70 years of experience in enzyme applications and formulation, consistent quality, an extensive product line, custom blending and packaging, and fast attention to customer requirements. The 2024 corporate press release calls it a family-owned business focused on enzymes for food, feed and industrial uses.

What the company does

EDC makes, standardises, blends, packages and sells enzyme preparations. These are biological catalysts used as processing aids or active ingredients. The company says it draws on two source types (Getting to Know EDC, July 2021):

Botanical enzymes extracted from plants: papain from papaya latex sourced from smallholder farmers in Africa and Asia; bromelain from pineapple stems; ficin from tropical fig latex; and Thistlezyme® aspartic protease from Cynara cardunculus flowers from Portugal.

Microbial enzymes produced by fermentation: solid-state fermentation (e.g., Aspergillus oryzae, A. niger) and submerged deep-tank fermentation (e.g., Bacillus amyloliquefaciens, Trichoderma reesei).

The Scranton plant carries out enzyme extraction and makes liquid and powdered preparations (New Hope Network). It runs more than 60 specialised enzyme assays, plus microbial, pathogen and metals testing (company website).

Business model and revenue model

Product sales: effectively all revenue appears to come from selling physical enzyme preparations in bulk, from single drums to dedicated truckloads (company website). There is no evidence of subscription, licensing or royalty income.

Hybrid manufacturer–distributor model: an older company description (reproduced by ZoomInfo) says EDC's own manufacturing and lab capabilities are supplemented by the research expertise of domestic and overseas manufacturers whose products EDC represents on an exclusive basis. This implies that part of the microbial catalogue is toll-produced or sourced from partners and then standardised, blended and sold by EDC. The split between own-produced and resold products is not publicly disclosed.

Embedded service element: technical sales staff with scientific backgrounds provide application support, custom blending and specification work. This is bundled into product pricing and not charged separately, as far as can be determined.

Pricing model: not publicly disclosed. B2B quote-based pricing by activity unit and volume is standard in this industry.

Value-chain position

EDC sits in the middle of the chain. Upstream are raw latex and plant material (papaya, pineapple, fig, thistle) and fermentation feedstocks or partner-made enzyme concentrates. EDC handles extraction, purification, standardisation on carriers such as maltodextrin, blending, QC and regulatory documentation. Downstream are industrial food, feed and supplement manufacturers. Some products are used as processing aids, which typically need no ingredient declaration. Others, such as supplement enzymes, are active ingredients.

Customer types and end-markets

End-marketRepresentative uses (company-stated)
Flavour modificationHydrolysed proteins, yeast extracts, enzyme-modified cheese (EMC), debittering
Pet foodDigest and palatant production, hairball treatments, pelleting
Meat & seafoodTenderising (including fajita strips and clam), meat flavours, sausage casings
DairyLactose-free milk, GOS, dulce de leche, cheesemaking (thistle rennet), EMC
BakingDough relaxation, crumb softness, shelf life (Fresh-N®), frozen dough proofing
Brewing & potable alcoholChill-haze reduction (papain), low-calorie beer, liquefaction, saccharification, sake
Starch processingMaltodextrin, dextrose in corn wet milling, high-maltose syrups; 2026 push on proteases in wet milling
Food supplements / nutraceuticalsDigestive-aid enzymes (papain, bromelain, lactase, alpha-galactosidase, Enzopharm® Plus)
Animal feed & agricultureSilage inoculants, feed enzymes, OMRI-listed organic feed enzymes
Juice, fruit & wineJuice yield, removal of fermentation by-products
OtherToothpaste, collagen and gelatin hydrolysis, peptide production, candy (invertase)

The website and trade-directory listings show the following end-markets:

Historically the company also served detergent protease, textile/denim, and pulp and paper markets, having started in brewing enzymes (New Hope Network). Its largest food-related sales are reported to be in protein modification and enzymes for flavour production and processing. Sales are reported to be concentrated in the Americas and Pacific Rim (New Hope Network).

Independent characterisation

EDC is best described as a specialty botanical-protease house with a broad, partly sourced microbial catalogue. Its strategic value depends on three hard-to-replicate assets:

  1. a Western Hemisphere papain, ficin and thistle-rennet production base;

  2. certification breadth: OMRI organic, Kof-K kosher (including kosher-for-Passover papain), IFANCA halal, non-GMO, vegan-suitable and gluten-free-claim-compatible grades;

  3. long-tenured application know-how.

Its weaknesses are sub-scale fermentation economics compared with global majors, reliance on tropical agricultural supply chains, and very small organisational depth.

Strategy

EDC publishes no annual report or investor day. Strategy is inferred from company communications.

Stated strategic themes (company communications, paraphrased):

  • Positioning as a customer-oriented, technically led enzyme partner that builds long-term relationships ("At EDC – Enzymes Are Our Business")

  • Exploiting its unique Western Hemisphere botanical protease production (papain, ficin, thistle rennet)

  • Clean-label innovation: the company cites recent work on organic-compliant certified enzymes, vegan-compliant enzymes and specialised flavour-releasing biocatalysts

Initiatives in the last 24 months (Oct 2024–Oct 2026):

Medium-term financial targets or guidance: not publicly disclosed. No cost programmes, ESG targets or transformation programmes have been announced.

Products & Services

Pricing is not publicly disclosed for any product. Launch years are given only where documented.

Botanical proteases (Family A)

ProductDescription & specificationTarget customers / applicationsLaunch / version
Panol®Powdered papain standardised to 100 and 300 MCU/mgSupplements, meat, brewing, flavours, pet foodLong-standing
Liquipanol®Liquid papain standardised to 100 and 200 TU/mgProtein hydrolysis, brewing chill-proofing, meatLong-standing
Liquipanol® RS 100Liquid papain processed without sulfites, 100 TU/mgClean-label and organic processing—
Liquipanol® RS 400Liquid no-sulfite papainOrganic and clean-label hydrolysis—
Enzeco® Purified Papain ConcentrateConcentrated papain powderSupplement manufacturers—
Enzeco® Purified Papain RS ConcentratePapaya latex processed without sodium metabisulfite; much lower SO2; botanical enzyme only; OMRI Listed®Organic food processing, organic animal feed, supplementsOMRI listings from 2014
Enzeco® Purified Papain RS 600No-sulfite papain standardised to 600 TU/mg on maltodextrinSupplements, hydrolysis—
Enzeco® Dual Protease RS 150No-sulfite papain plus bromelain blendMeat and clam tenderising—
Enzeco® BromelainPurified pineapple-stem protease at multiple activity levels (CDU, MCU, FCC-PU, BTU)Meat, flavours, baking, supplements, toothpaste, collagen hydrolysis, pet hairball treatments, pea/soy/whey hydrolysisEDC active in bromelain since early 1970s
Enzeco® Ficin 100Fig-latex cysteine protease, 100 MCU/mg on IP maltodextrin; lower deactivation temperature than papain or bromelain; non-GMO, clean labelMeat tenderising (thin cuts such as fajita strips), protein hydrolysis combined with papain or bromelainSep 2020
Ficin 250 BAPA/gHigher-standardised ficin grade announced with Ficin 100Protein hydrolysisAnnounced 2020
Enzeco® Ficin Liquid 50KFirst standardised liquid ficin; non-GMO, gluten-free, vegan-suitable, kosher and halal; GRASPlant-protein hydrolysis for meat alternatives, gelatin hydrolysis, EMC, milk/wheat/soy/pea/rice/oat proteinsEarly 2024
Enzeco® Ficin 50K (powder, flagged "NEW")Ficin grade marketed for meat tenderisingMeat processorsFlagged new Feb 2026
Thistlezyme®Aspartic protease extracted and partly purified from Cynara cardunculus flowers (Portugal); true vegetarian rennetCheesemaking (ewe, goat, cow milk); also gluten hydrolysis; currently approved for dairy onlyNot disclosed; dedicated site thistlerennet.com

Microbial proteases & peptidases (Family B)

ProductSource organism / specificationApplications
Enzeco® Fungal Protease MGNon-GMO A. oryzae; strong endo-protease, lower exo-protease; powder or micro-granulate up to 1,000,000 HUT/gFlavours, baking, meat, supplements, yeast cell-wall hydrolysis, EMC
Enzeco® Fungal Acid ProteaseNon-GMO A. niger; pH optimum 2.5–3.5, usable up to pH 6.5; kosher/halal alternative to pepsinPepsin replacement, flavour, FAN release, supplements
Enzeco® Fungal Protease 400A. oryzae acid and alkaline protease blend with LAP, carboxypeptidase and neutral protease; debitteringFlavour-enhanced hydrolysed proteins, EMC, baking
Enzeco® Protease 400 WFSame profile, fermented without wheat; suitable for "gluten-free" claimsGluten-free hydrolysed proteins and flavours
Enzeco® Protease FNPA. oryzae fungal neutral protease, pH 5–7, high aminopeptidase and acid carboxypeptidase; non-GMO multi-enzyme debittering complexFlavour modification, protein hydrolysis
Enzeco® DPPA. oryzae dipeptidyl aminopeptidase; used with or after another proteaseFlavours, collagen hydrolysis
Enzeco® Peptidase AO-30A. oryzae exo-peptidase with debittering side activitiesFlavours, EMC
Enzeco® Neutral Bacterial Protease 160SB. amyloliquefaciens; pH 5.5–8; very low amylaseFlavours, meat, protein hydrolysis
Enzeco® Alkaline Protease L-660Non-GMO B. licheniformis endopeptidase with side activitiesPet-food digests, yeast hydrolysis, peptides

Starch-hydrolysing carbohydrases (Family C)

ProductSource / specificationApplications
Enzeco® Bacterial Alpha AmylaseNon-GMO B. amyloliquefaciens; moderately heat-stable; RAU assayStarch liquefaction, supplements, brewing, baking, maltodextrin, pet-food pelleting, feed
Enzeco® Bacterial Amylase BLThermostable liquid alpha-amylase from B. licheniformis; optimum about 198°FHigh-temperature liquefaction, brewing, feed
Enzeco® Bacterial Amylase 25LNLiquid alpha-amylase, B. amyloliquefaciensLiquefaction, maltodextrin, brewing
Enzeco® Bacterial Amylase 10kDry alpha-amylase with protease side activityCereal processing, baking, brewing
Enzeco® Fungal Alpha AmylaseA. oryzae; liquid and powderHigh-maltose syrups (DE 40–45), baking, brewing, sweet potato
Fresh-N®Heat-resistant bacterial alpha-amylase; with or without dedusting oilMoisture, aroma and shelf-life extension in bread, cakes, cookies, brownies
Enzeco® Glucoamylase Powder RONon-GMO Rhizopus oryzae; hydrolyses alpha-1,4 and alpha-1,6 bondsCorn wet-milling dextrose, low-cal beer, silage, sake
Enzeco® Glucoamylase Powder ANA. niger, very pure; preservative-free for organic useLean/frozen dough proofing, brewing
Enzeco® Glucoamylase 400A. niger glucoamylase plus B. licheniformis pullulanaseBrewing, sweetness enhancement
Enzeco® Glucoamylase L 500Trichoderma reesei saccharifying glucoamylaseBrewing, potable alcohol
Adjuzyme®Liquid A. niger exo-glucosidaseBrewing fermentable sugars
Multizyme® IIFungal plus bacterial amylase blend with protease and beta-glucanaseCorn silage, animal feeds

Non-starch carbohydrases (Family D)

ProductSource / specificationApplications
Enzeco® InvertaseSaccharomyces cerevisiae; Sumner unitsSoft-centre candy, invert syrup, supplements
Enzeco® Invertase ANA. niger; pH 2.5–6, up to 70°CSyrups, candy, baking
Enzeco® Fungal LactaseNon-GMO A. oryzae acid-optimum beta-galactosidase; FCC ALULactase tablets/capsules, dry mixes, yogurt, GOS
Enzeco® Lactase NLKluyveromyces yeast lactase; YLULactose-free milk, dulce de leche, reduced-sugar dairy, GOS
Enzeco® Lactase KLHighly concentrated, filterable Kluyveromyces lactase for Aldose/FlexDos dosing systemsLactose-free milk
Enzeco® Alpha GalactosidaseNon-GMO A. niger; hydrolyses melibiose, stachyose, raffinoseSupplements (anti-flatulence), feed

Blends (Family E) and other lines (Family F)

ProductDescriptionApplications
Enzobake®A. oryzae protease and amylase blendBread dough conditioning, volume, anti-staling
Enzopharm® PlusSupplement blend: 23,500 SKB/g amylase; 58,000 HUT/g protease; 1.4 FIPU/mg lipase; 230 ACU/g hemicellulase; 1,750 FCC ALU/g lactaseDigestive-enzyme supplements
Septizyme®Trade name listed in FoodMaster directory—
Cellulases, lipases/esterases, pectinases, xylanasesListed in Bloomberg profileJuice, wine, feed, flavours

Services

  • Custom blending and packaging

  • Technical application support from the technical sales team (company claims 90+ combined years of food and enzyme experience)

  • More than 60 enzyme activity assays, published assay methods (e.g., FCC-PU plant protease method), and regulatory documentation (kosher, halal, OMRI, non-GMO, GRAS)

Financial Narrative

No audited or management financial statements are publicly available. EDC is private and files nothing with the SEC. All tables below are left blank (not publicly disclosed) so that no figure is invented. The only external datapoints are third-party revenue estimates, shown separately.

Income statement

Revenue CAGR: not publicly disclosed.

Qualitative financial commentary

Without financials, trend analysis has to rely on operating signals.

Gross-margin drivers. Botanical enzymes depend on agricultural raw materials: papaya latex from smallholders in Africa and Asia, pineapple stems, fig latex, and Portuguese thistle. Their input costs are therefore exposed to crop yields, weather, logistics and FX. EDC's own blog post titled "So…You Got a Great Deal on Bromelain" suggests price competition in commodity bromelain. Value-added grades should carry premiums: no-sulfite OMRI papain, liquid ficin, and gluten-free-claim proteases.

Fixed-cost base. The business runs one plant in Scranton plus a small Manhattan office. Operating leverage is likely high, but scale is limited.

Capital intensity. No disclosed capex. The 1990s move to Scranton was the last documented major facility investment.

Signals of stability rather than distress. These include continued product launches (2020, 2024, 2026), new OMRI listings in 2024 and 2025, an orderly leadership succession (2024), trade-show presence (IPPE, Meat Conference, IFT 2026) and active content marketing in 2026. One aggregator (Nombase) labels the company "out of business", which is contradicted by the 2025–2026 OMRI listings, website activity and the 2026 IFT sponsorship. That label is treated as erroneous.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Analyst Product Family Details

Analyst product familyContentsKey brands

A. Botanical proteases

Papain (powders, liquids, concentrates, no-sulfite/OMRI grades), bromelain, ficin, thistle rennet

Panol®, Liquipanol®, Enzeco® Purified Papain, Enzeco® Bromelain, Enzeco® Ficin, Thistlezyme®

B. Microbial proteases & peptidases

Fungal (A. oryzae, A. niger) and bacterial (Bacillus) proteases; debittering peptidases; DPP

Enzeco® Fungal Protease, Protease FNP, 400 / 400 WF, DPP, Peptidase AO-30, Neutral Bacterial Protease 160S, Alkaline Protease L-660

C. Starch-hydrolysing carbohydrases

Bacterial and fungal alpha-amylases, glucoamylases, pullulanase blends

Enzeco® Bacterial Alpha Amylase, Amylase BL/25LN/10k, Fungal Alpha Amylase, Glucoamylase RO/AN/400/L 500, Adjuzyme®, Fresh-N®

D. Non-starch carbohydrases

Invertases, lactases, alpha-galactosidase

Enzeco® Invertase, Invertase AN, Fungal Lactase, Lactase NL/KL, Alpha Galactosidase

E. Blends & multi-enzyme systems

Baking, supplement and feed blends

Enzobake®, Enzopharm® Plus, Multizyme® II, Enzeco® Dual Protease RS 150, Septizyme®

F. Other catalogue lines (not detailed in this research)

Cellulases, lipases/esterases, pectinases, xylanases

Listed by Bloomberg profile

Provider Details

ProviderEstimateDate observedComment

ZoomInfo

about USD 7.5M annual revenue

2026

Model-based estimate

LeadIQ

USD 10–25M range

Mar 2026

Model-based range

Discrepancy

Estimates differ by up to about 3x

—

Neither verifiable; treat as order-of-magnitude only (single-digit to low-double-digit USD millions)

Capital Markets

ItemStatus

Share price performance (1/3/5-year)

Not applicable (private)

Analyst consensus

None; no sell-side coverage

Credit ratings (Moody's / S&P / Fitch)

None identified

External funding

None recorded (Tracxn, Nombase)

Capital markets metric (not applicable / not disclosed)

FY2021

Analyst Conclusions

Management guidance: none published.

Consensus growth expectations: none; no analyst coverage.

Bull case

  1. Scarcity value of the botanical base. As the self-described only Western Hemisphere producer of papain, ficin and thistle rennet, EDC holds a supply-security asset that U.S. food, pet and supplement manufacturers value more when tariffs and logistics are unstable.

  2. Clean-label tailwinds monetised through premium grades. No-sulfite OMRI papain, gluten-free-compatible proteases, vegan and halal/kosher ficin, and four new OMRI feed listings in 2024–2025 show an active pipeline into premium niches.

  3. New application vectors: corn wet-milling proteases (as SO2 costs rise), plant-protein hydrolysis, meat tenderising and ruminant GHG enzymes could add volume without a new plant.

Bear case

  1. Structural scale gap. Majors such as Novonesis grew 7% organically with a 37% adj. EBITDA margin in FY2025 and guide to 5–7% growth in 2026. EDC's microbial catalogue, partly sourced from partners, risks commoditisation.

  2. Concentrated operational risk: one plant, a small team (aggregators estimate fewer than 50 people), and tropical agricultural inputs.

  3. Low visibility and data noise: no disclosures, an aggregator wrongly flagging the company as "out of business", and dated web copy can hurt procurement qualification with large customers.

Key catalysts and monitorables (next 12 months)

  • Renewal of OMRI listings expiring 1 Dec 2026

  • Further ficin or Thistlezyme® launches, or regulatory approvals beyond dairy for Thistlezyme®

  • Commercial results from the corn wet-milling protease initiative

  • Any public progress on ruminant GHG enzymes

  • Changes in the Moodie advisory role or further leadership moves

  • Strategic approaches from consolidators, or any ownership change

  • Raw-material supply disruptions (papaya latex)

  • U.S. tariff changes on imported enzyme inputs

Analyst verdict

Enzyme Development Corporation is not the public company named in the input brief. It is a durable, family-owned niche specialist that has survived more than seven decades in an industry steadily consolidated by multinational biosolutions groups. Its defensibility does not come from scale, which it lacks; aggregator estimates put revenue between roughly USD 7.5M and USD 25M and headcount at about 18 to 50. It comes from a narrow but real asset: domestic production of botanical proteases (papain, ficin, thistle rennet) that the company says no other Western Hemisphere producer makes. That base is complemented by unusually broad certification coverage and long-tenured application expertise across flavours, pet food, meat, dairy, baking, brewing, starch and supplements.

The evidence since 2020 points to a company in steady, low-key renewal rather than decline. It launched Ficin 100 in 2020 and Ficin Liquid 50K in 2024, and flagged a new ficin grade in 2026. It added OMRI feed listings in 2024 and 2025, completed an orderly presidential succession in January 2024, and is visibly pursuing adjacent markets such as corn wet milling and ruminant emissions.

The central strategic tension is that its microbial enzyme lines, likely the larger share of its catalogue, compete head-on with far better-capitalised majors. Its botanical lines are exposed to tropical supply and to price competition from Asian producers. A single plant and a thin management bench add operational fragility.

For counterparties, EDC looks like a credible, specialised supplier, best used for botanical proteases, certified clean-label grades and custom technical work rather than high-volume commodity enzymes. For acquirers, it is a plausible bolt-on whose main value is its papain/ficin/thistle know-how and certifications. Absolute financial conclusions are not possible: no audited financials, segment data or ownership details are public, and any valuation or credit view would need direct due diligence.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundSource

Wallace Chavkin

Chief Executive Officer / key principal (per D&B)

Tenure, age and education not publicly disclosed. Whether he is a member of the owning family is not confirmed.

D&B

Brian Murdoch

President (since 1 Jan 2024)

Previously Vice President of EDC; extensive experience in fermentation and industrial enzyme applications; handles day-to-day management

Company press release; Pet Food Processing; Food Business News

Peter Moodie

Senior Management Advisor (since 1 Jan 2024)

Joined EDC in 1987; President 2010–2023; IFT member since 1976; now leads longer-term growth projects

Company press release; IFT Food Technology

Christina Barsa

Director, Strategic Accounts (per FoodMaster); LeadIQ lists a "C. B." as Vice President (Mar 2026), likely the same person, unconfirmed

Author of corporate web content

FoodMaster; LeadIQ; company website

Andrea Dreyfus

Laboratory / QC Laboratory Manager

Presented an IFT poster comparing ficin, papain and bromelain

Company blog; LeadIQ

David Drasdauksas

General Manager, Scranton

Key principal for the Scranton site

D&B; Buzzfile

Competitive Landscape

Key Competitors

CompetitorSegment overlap with EDCOwnershipRelative positioningVerified datapoints (source)

Novonesis (Novozymes + Chr. Hansen)

Microbial carbohydrases and proteases; dairy (lactase); brewing; baking; feed

Public (Copenhagen)

Global leader; vastly larger

FY2025 organic sales growth 7%; adj. EBITDA margin 37.1%; FY2026 guidance 5–7% organic growth (Novonesis, Feb 2026)

IFF (former Genencor / DuPont N&B)

Food, brewing, baking, starch enzymes

Public (NYSE)

Global major

—

dsm-firmenich

Dairy, baking, brewing enzymes

Public (Euronext)

Global major

—

AB Enzymes (ABF Ingredients)

Baking, food, feed enzymes

Subsidiary of Associated British Foods

Large specialist

—

Amano Enzyme

Food and supplement enzymes, proteases, lactase

Private (Japan)

Strong in supplements and flavour

—

Kerry Group (incl. Biosearch / enzymes)

Food and pharma enzymes, bromelain/papain

Public (Euronext Dublin)

Taste and nutrition major

—

Advanced Enzyme Technologies

Supplement, food and feed enzymes, including botanical proteases

Public (NSE/BSE, India)

Low-cost Asian specialist

—

BIO-CAT

Food and supplement enzymes

Private (USA)

U.S. specialty peer

—

Biocatalysts Ltd (BRAIN Biotech)

Flavour/protein hydrolysis specialty enzymes

Subsidiary of BRAIN Biotech (public)

Specialty flavour peer

—

Specialty Enzymes & Probiotics; Deerland; National Enzyme Co.

Supplement enzymes

Private

U.S. supplement-channel competitors

—

Creative Enzymes

Lipase and food enzymes

Private

Named alongside EDC in lipase food-enzyme market coverage

ZoomInfo news headline

VTR Biotech

Feed enzymes

Public (SZSE: 300381)

Expanding into the EU and Latin America (Brazil subsidiary set up in 2026)

Wikipedia (Apr 2026)

Fornia BioSolutions; American Biosystems; Ultreze Enzymes

Various enzymes

Private

Listed by Crunchbase as alternatives

Crunchbase

Asian and African papain/bromelain producers (various)

Commodity papain and bromelain

Mostly private

Price competition in botanical proteases

EDC blog implies bromelain price pressure

Peer Comparison FY2025

MetricEDCNovonesis

FY2025 revenue

Not disclosed (estimates about USD 7.5M or USD 10–25M)

—

FY2025 organic growth

—7%

FY2025 adj. EBITDA margin

—37.1%

Western Hemisphere papain production

Yes (sole producer, company claim)

No

“—” = not publicly disclosed.

Recent Developments

Not identified in the period: * contract wins, guidance revisions, litigation, regulatory actions, restructurings, layoffs or acquisitions.

Company Snapshot

18

Employees

1953

Founded

NY, US

Headquarters

SWOT Analysis

Strengths

  • Unique supply position: company states it is the only papain producer in the Western Hemisphere, and also the only regional producer of ficin and thistle rennet (company website and blog).
  • Organic franchise: multiple active OMRI listings dating from 2014 to 2025 across processing aids and livestock feed (OMRI registry).
  • Certification breadth: papain is non-GMO, vegan-friendly, Kof-K kosher and IFANCA halal certified; kosher-for-Passover papain is offered (company website; FoodMaster).
  • Longevity and know-how: founded 1953; the Scranton team cites 100+ combined years of enzyme experience, and the technical sales team 90+ years (company website).
  • Broad catalogue: 40+ named SKUs spanning botanical, fungal and bacterial sources and 10+ end-markets.
  • QC depth: more than 60 specialised assays in-house, plus published methods such as FCC-PU (company website).
  • Orderly succession: planned Moodie-to-Murdoch handover with a transition period (press release, Jan 2024).

Weaknesses

  • Scale: an estimated 11–50 employees and USD 7.5–25M revenue (aggregators) versus multi-billion-euro competitors.
  • Single plant: all production and shipping go through Scranton (company website), a single point of failure.
  • Dependence on partner manufacturers for part of the catalogue (exclusive-representation model per company description), which limits margin and control.
  • No disclosed patent portfolio or proprietary strain engineering.
  • Thin public profile and dated web content: homepage copy still says "over 65 years" while other pages say "70+" (company website), which weakens credibility in a digital-first buying environment.
  • Data-quality noise: one aggregator lists the company as "out of business" (Nombase), creating counterparty-risk perceptions.

Opportunities

  • Meat alternatives and plant-protein hydrolysis via Ficin Liquid 50K (press release, 2024).
  • Corn wet milling as SO2 costs spike (company blog, May 2026).
  • Ruminant GHG-reduction enzymes (Moodie project; IFT Food Technology).
  • Thistle rennet expansion beyond dairy approval (company website notes other applications can be added).
  • Organic livestock feed: OMRI feed listings added in 2024 and 2025 (OMRI).
  • Near-shoring and supply-security demand from U.S. food makers, where a domestic botanical protease source matters.

Threats

  • Global majors' scale and pricing: Novonesis reports 37.1% adj. EBITDA margin and 7% organic growth in FY2025, funding aggressive innovation (Novonesis).
  • Commodity price pressure in bromelain and papain (EDC's own "great deal on bromelain" commentary).
  • Raw-material and geopolitical risk in African and Asian papaya latex supply (Getting to Know EDC).
  • Regulatory change: Japan's CAA notification rules (Sep 2025) and FDA gluten-free rules have already forced product changes (company blog).
  • Certification lapses: several OMRI listings expire 1 Dec 2026 and need renewal (OMRI).
  • Asian low-cost competitors expanding globally, e.g., VTR Biotech's 2026 Brazil subsidiary and EU feed-enzyme approvals (Wikipedia).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jan 2024 (context)Murdoch becomes President; Moodie becomes Senior Management Advisor Press releaseLeadership succession
Early 2024 (context)Enzeco® Ficin Liquid 50K launched Press releasePlant-protein and EMC hydrolysis
Jan 2025Content cadence
21 Mar 2025Not determinable
9 Jun 2025Carbohydrase catalogue page updated Company website metadataPortfolio maintenance
Jul 2025Content cadence
18 Aug 2025Not determinable
Sep 2025Advisory on Japan's CAA Notice No. 552 (10 Sep 2025) on enzyme-producing microorganism names; EDC working with ETA Company blogRegulatory compliance for Japanese market
10 Sep 2025News item logged by Crunchbase (likely the same regulatory topic, unconfirmed)—
25 Sep 2025Two new OMRI livestock-feed ingredient listings (edc-22408, edc-22410)Organic feed enzyme expansion
4 Nov 2025Not determinable
31 Jan 2026Tracxn reports 3 tracked employees (methodological artefact; conflicts with other sources)Data-quality caution
17 Feb 2026Protease catalogue updated; Ficin 50K flagged "NEW" Company website metadataProduct launch / relaunch
Mar 2026LeadIQ reports about 18 employees and a USD 10–25M revenue rangeThird-party sizing
16 Apr 2026Sponsor, NY IFT Suppliers' Day 2026 ZoomInfoCustomer outreach
May 2026"The Sulfur Squeeze" post on proteases in corn wet milling amid record sulfur prices Company blogNew end-market push into starch processing
Jul–Aug 2026"From Fig Tree to Frying Pan" post on ficin meat tenderising Company blogFicin commercialisation
1 Dec 2026 (upcoming)Expiry of several OMRI listings (edc-22410, edc-5677, edc-20159, edc-20036); renewal neededCertification continuity
2026 (undated)IFT Food Technology coverage of the role transitions and Moodie's three growth projectsStrategic visibility

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.